Celerion Majority Investment

THL Partners has made a majority investment in Celerion, a clinical pharmacology and bioanalytical sciences company, marking a significant follow-on funding event for the firm. This capital infusion is earmarked for expanding Celerion's clinical and bioanalytical capabilities. The investment aims to accelerate the development of new therapies by Celerion's pharmaceutical and biotechnology partners.